Mogrify: Using Big Data To Transform Development Of Cell Therapies
Executive Summary
Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.
You may also be interested in...
Astellas’s Venture Arm Is Focused On Flexibility But Avoiding Hype
VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.